Arcellx, Inc. (NASDAQ:ACLX) Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd decreased its holdings in shares of Arcellx, Inc. (NASDAQ:ACLX) by 75.4% during the 3rd quarter, Holdings Channel.com reports. The firm owned 3,904 shares of the company’s stock after selling 11,955 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Arcellx were worth $326,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in ACLX. Wellington Management Group LLP lifted its position in Arcellx by 15.2% during the third quarter. Wellington Management Group LLP now owns 20,968 shares of the company’s stock worth $1,751,000 after buying an additional 2,768 shares during the period. Quarry LP purchased a new position in shares of Arcellx during the 3rd quarter worth about $125,000. RA Capital Management L.P. boosted its position in shares of Arcellx by 15.4% in the third quarter. RA Capital Management L.P. now owns 1,851,479 shares of the company’s stock worth $154,617,000 after acquiring an additional 247,465 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in Arcellx by 67.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 79,936 shares of the company’s stock valued at $6,675,000 after purchasing an additional 32,119 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in Arcellx by 5.7% in the third quarter. Janus Henderson Group PLC now owns 2,011,950 shares of the company’s stock valued at $168,026,000 after purchasing an additional 109,332 shares during the period. Hedge funds and other institutional investors own 96.03% of the company’s stock.

Arcellx Trading Down 1.7 %

NASDAQ ACLX opened at $82.03 on Wednesday. The company’s fifty day simple moving average is $89.08 and its 200-day simple moving average is $72.94. The stock has a market cap of $4.44 billion, a P/E ratio of -115.53 and a beta of 0.25. Arcellx, Inc. has a 52 week low of $47.88 and a 52 week high of $107.37.

Arcellx (NASDAQ:ACLX) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.06. Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. The company had revenue of $26.03 million during the quarter, compared to analysts’ expectations of $35.21 million. On average, research analysts expect that Arcellx, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. UBS Group increased their price target on shares of Arcellx from $106.00 to $114.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. Barclays raised Arcellx to a “strong-buy” rating in a research report on Friday, November 29th. HC Wainwright restated a “buy” rating and set a $115.00 price target on shares of Arcellx in a research note on Tuesday, December 10th. Truist Financial lifted their price objective on Arcellx from $87.00 to $136.00 and gave the company a “buy” rating in a research note on Tuesday, November 12th. Finally, Piper Sandler increased their target price on shares of Arcellx from $91.00 to $115.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Thirteen analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Arcellx has a consensus rating of “Buy” and an average price target of $105.93.

Insider Buying and Selling at Arcellx

In other Arcellx news, Director Kavita Patel sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $89.69, for a total value of $134,535.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 52,001 shares of company stock worth $5,402,443 in the last 90 days. 6.24% of the stock is owned by corporate insiders.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).